← Leaderboards
William George Wierda
University Of Tx Md Anderson Can Ctr
$4,170,218
Attributed
$4,647,240
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $994.4K · FY2009–16$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$4,647,240 · 3
By mechanism
P01$3,081,596 · 1
R01$954,044 · 1
R21$611,600 · 1
Top collaborators
- William K Plunkett3 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Chengming Zhu$1,635,765
- Varsha Gandhi$2,500,715
- Junjie Chen$28,940,212
- Michael W Andreeff$17,991,896
- Rakesh Kumar$4,719,399
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsLaboratoriesBaseReportingDrug Effect DisorderCancer CenterLaboratory StudyDesignSamplingStructureChronic Lymphocytic LeukemiaApplications GrantsSiteNew AgentsCollectionCorrelative StudyAdvisory CommitteesCollaborationsCritical PathwaysBiomedical InformaticsClinical ManagementData CollectionBiostatistics CoreClinical Data
Grant awards (10)
Clinical Program$519,497
P01 · FY2016 · CA · contact PI
Clinical Program$637,192
P01 · FY2015 · CA · contact PI
Clinical Program$630,885
P01 · FY2014 · CA · contact PI
Sapacitabine therapy to create synthetic lethality in DNA repair-deficient CLL$318,015
R01 · FY2014 · CA · contact PI
Clinical Program$627,478
P01 · FY2013 · CA · contact PI
Sapacitabine therapy to create synthetic lethality in DNA repair-deficient CLL$308,179
R01 · FY2013 · CA · contact PI
Clinical Program$666,544
P01 · FY2012 · CA · contact PI
Sapacitabine therapy to create synthetic lethality in DNA repair-deficient CLL$327,850
R01 · FY2012 · CA · contact PI
8-Chloro-Adenosine for Treatment of CLL (IND 68,229)$305,800
R21 · FY2010 · CA · contact PI
8-Chloro-Adenosine for Treatment of CLL (IND 68,229)$305,800
R21 · FY2009 · CA · contact PI